Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2006 1
2007 2
2008 4
2009 1
2010 6
2011 5
2012 5
2013 5
2014 7
2015 15
2016 15
2017 18
2018 24
2019 17
2020 20
2021 21
2022 40
2023 33
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. Greenberg PL, et al. J Natl Compr Canc Netw. 2022 Feb;20(2):106-117. doi: 10.6004/jnccn.2022.0009. J Natl Compr Canc Netw. 2022. PMID: 35130502
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.
Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Shah MV, et al. Blood Cancer J. 2022 Jul 8;12(7):106. doi: 10.1038/s41408-022-00703-8. Blood Cancer J. 2022. PMID: 35803921 Free PMC article.
A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Al-Kali A, Aldoss I, Atherton PJ, Strand CA, Shah B, Webster J, Bhatnagar B, Flatten KS, Peterson KL, Schneider PA, Buhrow SA, Kong J, Reid JM, Adjei AA, Kaufmann SH. Al-Kali A, et al. Cancer Med. 2023 Dec;12(23):21229-21239. doi: 10.1002/cam4.6701. Epub 2023 Nov 13. Cancer Med. 2023. PMID: 37960985 Free PMC article. Clinical Trial.
Etiologies of Extreme Thrombocytosis: A Contemporary Series.
Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, Litzow M, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS. Hsieh RW, et al. Mayo Clin Proc. 2019 Aug;94(8):1542-1550. doi: 10.1016/j.mayocp.2019.01.041. Mayo Clin Proc. 2019. PMID: 31378229
Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Tefferi A, et al. Blood Cancer J. 2018 Mar 7;8(3):29. doi: 10.1038/s41408-018-0067-6. Blood Cancer J. 2018. PMID: 29515114 Free PMC article. Clinical Trial.
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Gangat N, et al. Am J Hematol. 2021 Jul 1;96(7):781-789. doi: 10.1002/ajh.26186. Epub 2021 May 6. Am J Hematol. 2021. PMID: 33844862 Free PMC article.
SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.
Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. Mangaonkar AA, et al. Haematologica. 2022 May 1;107(5):1189-1192. doi: 10.3324/haematol.2021.280463. Haematologica. 2022. PMID: 35142154 Free PMC article. No abstract available.
220 results